1. Zhang, Wancong, Xie, Xuqi, Huang, Zijian, Zhou, Jianda, Tang, Shijie. 2022. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM. In Frontiers in immunology, 13, 919145. doi:10.3389/fimmu.2022.919145. https://pubmed.ncbi.nlm.nih.gov/36211371/
2. Zhao, Kai, Bai, Xuexue, Wang, Xiao, Li, Wei, Wang, Shiyong. 2023. Insight on the hub gene associated signatures and potential therapeutic agents in epilepsy and glioma. In Brain research bulletin, 199, 110666. doi:10.1016/j.brainresbull.2023.110666. https://pubmed.ncbi.nlm.nih.gov/37192718/
3. Fan, Li, Li, Hai, Wang, Weihua. 2020. Long non-coding RNA PRRT3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy. In Experimental physiology, 105, 793-808. doi:10.1113/EP088011. https://pubmed.ncbi.nlm.nih.gov/32086850/
4. Ma, Andi, Sun, Yukai, Ogbodu, Racheal O, Deng, Haibin, Zhou, Hui. 2023. Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data. In Functional & integrative genomics, 23, 104. doi:10.1007/s10142-023-01019-x. https://pubmed.ncbi.nlm.nih.gov/36976410/